Advertisement

Clinical and Translational Oncology

, Volume 14, Issue 5, pp 321–322 | Cite as

Biomarker testing in non-small cell lung cancer: to move forward with quality

  • Rolf StahelEmail author
Editorial

References

  1. 1.
    Garrido P, de Castro J, Concha Á et al (2012) Guidelines for biomarker testing in advanced non-small-cell lung cancer (NSCLC). A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol 14:338–349PubMedGoogle Scholar
  2. 2.
    Felip E, Gridelli C, Baas P et al; panel members (2010) Metastatic non-small cell lung cancer: consensus on pathology and molecular tests, first line, second line, and third line. 1st ESMO Consensus Conference in Lung Cancer, Lugano 2010. Ann Oncol 22:1507–1519CrossRefGoogle Scholar
  3. 3.
    Pirker R, Herth F, Kerr K et al; European EGFR Workshop (2010) Consensus for EGFR mutation testing in non-small cell lung cancer. Results from a European Workshop. J Thorac Oncol 5: 1706–1712PubMedCrossRefGoogle Scholar
  4. 4.
    Thunnisson E, Kerr, K, Herth F et al (2012) The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 76:1–18CrossRefGoogle Scholar
  5. 5.
    Sequist LV, Heist RS, Shaw AT et al (2011) Implementing multiplexed genotyping on non-small cell lung cancer in routine clinical practice. Ann Oncol 22:2616–2624PubMedCrossRefGoogle Scholar
  6. 6.
    Polity K, Lynch TJ (2012) Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. Clin Cancer Res [Epub ahead of print]Google Scholar

Copyright information

© Feseo 2012

Authors and Affiliations

  1. 1.Clinic of OncologyUniversity HospitalZürichSwitzerland

Personalised recommendations